Profound Medical Corp. - common stock (NQ:PROF)

7.620 -0.760 (-9.07%)

Streaming Delayed Price Updated: 4:00 PM EST, Jan 14, 2026 Add to My Watchlist

Price and Volume

Volume	470,609
Open	8.390
Bid (Size)	7.690 (500)
Ask (Size)	8.690 (2,000)
Prev. Close	8.380
Today's Range	7.545 - 8.545
52wk Range	3.760 - 8.950
Shares Outstanding	20,208,948
Dividend Yield	N/A

Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News

Profound Surpasses 2025 TULSA-PRO® Installed Base Goal

January 12, 2026

Company’s year-end TULSA-PRO installed base stood at 78 systems; qualified sales pipeline grew to 97 new systems

From Profound Medical Corp.

Via GlobeNewswire

Johns Hopkins Medicine Treats First Commercial TULSA-PRO® Case

January 06, 2026

Profound Medical marks major milestone as the hospital launches its state-of-the-art iMRI suite to expand access to advanced prostate care

From Profound Medical Corp.

Via GlobeNewswire

Performance

YTD	-0.5%	-0.5%
1 Month	-0.9%	-0.9%
3 Month	+30.7%	+30.7%
6 Month	+33.7%	+33.7%
1 Year	+2.3%	+2.3%

More News

Earnings Scheduled For November 13, 2025 ↗

November 13, 2025

Via Benzinga

Earnings Scheduled For August 14, 2025 ↗

August 14, 2025

Via Benzinga

InvestorNewsBreaks – Profound Medical Corp. (NASDAQ: PROF; TSX: PRN) Closes $36 Million Registered Direct Offering

December 31, 2025

Via Investor Brand Network

Profound Medical Corp. Announces Closing of Private Placement

December 30, 2025

From Profound Medical Corp.

Via GlobeNewswire

Profound Medical Corp. Announces Upsize of Private Placement

December 24, 2025

From Profound Medical Corp.

Via GlobeNewswire

Profound Medical Corp. Closes $36 Million Registered Direct Offering; Expects to Complete Subsequent Private Placement On or Before December 30th

December 23, 2025

From Profound Medical Corp.

Via GlobeNewswire

Profound Medical Corp. Announces Pricing of up to $40 Million Financing Comprised of a $36 Million Registered Direct Offering and a Subsequent $4 Million Private Placement

December 19, 2025

From Profound Medical Corp.

Via GlobeNewswire

Profound Medical Reports Strong Third Quarter 2025 Financial Results

November 13, 2025

From Profound Medical Corp.

Via GlobeNewswire

Profound Medical Announces Strategic Distribution Agreement with Getz Healthcare to Bring TULSA-PRO® to Australia and New Zealand

November 12, 2025

From Profound Medical Corp.

Via GlobeNewswire

Stanford Medicine’s Dr. Pejman Ghanouni Receives RSNA’s Cum Laude Award for CAPTAIN Perioperative Data Presentation

December 04, 2025

From Profound Medical Corp.

Via GlobeNewswire

Profound Medical Inks Exclusive Distribution Agreement for TULSA-PRO® and Sonalleve® with Al Faisaliah Medical Systems in Saudi Arabia

November 11, 2025

From Profound Medical Corp.

Via GlobeNewswire

Profound Medical to Launch AI-Powered BPH Module, Present New TULSA-PRO® Clinical Data, at RSNA and SUO Meetings

November 28, 2025

From Profound Medical Corp.

Via GlobeNewswire

Profound Medical Regains Exclusive Distribution Rights for TULSA-PRO® in Canada from Knight

November 10, 2025

From Profound Medical Corp.

Via GlobeNewswire

Profound Medical Celebrates The Hong Center’s 200th Independent TULSA Procedure for Prostate Disease

November 18, 2025

From Profound Medical Corp.

Via GlobeNewswire

Profound Medical to Participate in the Stifel 2025 Healthcare Conference

October 14, 2025

From Profound Medical Corp.

Via GlobeNewswire

Profound Medical Congratulates the Busch Center for Achieving 500th TULSA Procedure Milestone

October 16, 2025

From Profound Medical Corp.

Via GlobeNewswire

Profound Medical Achieves Record Preliminary Unaudited Revenue for the 2025 Third Quarter

October 07, 2025

From Profound Medical Corp.

Via GlobeNewswire

Texas Prostate and Dallas Medical Center Launch First-of-its-Kind TULSA Program, Expanding Access to Advanced Prostate Treatment

September 23, 2025

From Profound Medical Corp.

Via GlobeNewswire

Profound Medical to Participate in Lake Street’s 9th Annual Best Ideas Growth Conference

August 28, 2025

From Profound Medical Corp.

Via GlobeNewswire

Profound Medical Posts Wider Loss in Q2 ↗

August 14, 2025

Via The Motley Fool

Profound Medical Announces Second Quarter 2025 Financial Results

August 14, 2025

From Profound Medical Corp.

Via GlobeNewswire

Profound Medical to Release Second Quarter 2025 Financial Results on August 14 – Conference Call to Follow

July 24, 2025

From Profound Medical Corp.

Via GlobeNewswire

Profound Medical Announces First Commercial BPH Patient Treatment Using TULSA-PRO® with TULSA-AI® Volume Reduction

June 10, 2025

From Profound Medical Corp.

Via GlobeNewswire

Frequently Asked Questions

Is Profound Medical Corp. - common stock publicly traded?

Yes, Profound Medical Corp. - common stock is publicly traded.

What exchange does Profound Medical Corp. - common stock trade on?

Profound Medical Corp. - common stock trades on the Nasdaq Stock Market

What is the ticker symbol for Profound Medical Corp. - common stock?

The ticker symbol for Profound Medical Corp. - common stock is PROF on the Nasdaq Stock Market

What is the current price of Profound Medical Corp. - common stock?

The current price of Profound Medical Corp. - common stock is 7.620

When was Profound Medical Corp. - common stock last traded?

The last trade of Profound Medical Corp. - common stock was at 01/14/26 04:00 PM ET

What is the market capitalization of Profound Medical Corp. - common stock?

The market capitalization of Profound Medical Corp. - common stock is 153.99M

How many shares of Profound Medical Corp. - common stock are outstanding?

Profound Medical Corp. - common stock has 154M shares outstanding.

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.